Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
Bronchodilator Responsiveness (BDR) prevalence in patients with chronic airway diseases receiving treatment ranges from 18% to 30%, being modestly lower with the 2021 than with the 2005 European Respiratory Society/American Thoracic Society criteria, and it is associated with lower lung function and greater symptom burden.
These observations question the validity of BDR as a key diagnostic tool for asthma managed in clinical practice or as a standard inclusion criterion for clinical trials of asthma and instead suggest that BDR be considered a treatable trait for chronic airway disease.
Measurements and Main Results
3,519 patients were studied with a physician-assigned diagnosis of asthma, 833 with a diagnosis of asthma + COPD, and 2,436 with a diagnosis of COPD.
The prevalence of BDR was 19.7% (asthma), 29.6% (asthma + COPD), and 24.7% (COPD) using 2005 criteria and 18.1%, 23.3%, and 18.0%, respectively, using 2021 criteria.
Using 2021 criteria in patients diagnosed with asthma, BDR was associated with higher fractional exhaled nitric oxide; lower lung function; higher symptom burden; more frequent hospital admissions; and greater use of triple therapy, oral corticosteroids, or biologics. In patients diagnosed with COPD, BDR (2021) was associated with lower lung function and higher symptom burden.
Puedes leer el artículo completo aquí: https://pubmed.ncbi.nlm.nih.gov/38029294/
Autores: Richard Beasley, Rod Hughes, Alvar Agusti, Peter Calverley, Bradley Chipps, Ricardo Del Olmo, Alberto Papi, David Price, Helen Reddel, Hana Müllerová, Eleni Rapsomaniki.
Noticias relacionadas
COPD in the 21st Century
COPD in the 21st Century: Alvar Agustì and Rosa Faner are part of this book, being authors of chapter 4. Scientists and clinicians across many countries have made great efforts to understand this important disease, and these have yielded positive results.
Coffee Talk: CADSET-explaining the lung function tracker tool
The latest episode of Coffee Talk sees co-chairs of the ERS Clinical Research Collaboration CADSET, Prof. Erik Melén and Prof. Rosa Faner, catch up to discuss the topic of the new lung function tracker tool.
Lung Tissue Multi-Layer Network Analysis Uncovers the Molecular Heterogeneity of COPD
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous condition. We hypothesized that the unbiased integration of different COPD lung omics using a novel multi-layer approach may unravel mechanisms associated with clinical characteristics.
From treatable traits to GETomics in airway disease: moving towards clinical practice
The treatable traits approach represents a strategy for patient management. It is based on the identification of characteristics susceptible to treatments or predictive of treatment response in each individual patient.
Resumen del Primer Encuentro Anual de Pacientes de Chiesi – Chiesi PatientTalks
Primer Encuentro Anual de Pacientes de Chiesi: punto de encuentro de referencia y foro de debate y discusión para pacientes, profesionales sanitarios, así como otros agentes del sector salud, con el fin de ayudar a visibilizar sus necesidades.
V Congreso Experiencia de Paciente
El 22/02/2024 se celebrará el V Congreso del Instituto de Experiencia del Paciente (IEXP). El Dr. Alvar Agustí participará en la Mesa: Innovación en procesos y tecnología desde la experiencia de paciente.
Artículos
COPD
- 759785·Richard Beasley et Al – Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
- 759788·Alvar Agustí, Rod Hughes, Eleni Rapsomaki, Barry Make, Ricardo Del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzen, Jørgen Vestbo, Hana Mullerova – The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort
- 759883·Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí. – From treatable traits to GETomics in airway disease: moving towards clinical practice
- 768799·Surya P Bhatt Richard Casaburi Alvar Agusti et Al. Chronic obstructive pulmonary disease: hiding in plain sight, a Statement from the COPD Foundation Medical and Scientific Advisory Committee
- 768885·Miguel Angel Martinez-García, Alvar Agustí. – Microbiological Monitoring in Therapeutic Trials in Chronic Obstructive Pulmonary Disease
Imagen obtenida en artículo origninal.
